½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1338972

¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, Á¡À¯À², ±Ô¸ð, µ¿Çâ, »ê¾÷ ºÐ¼® º¸°í¼­ : Ä¡·áÁ¦ À¯Çüº°, Ä¡·áÁ¦ À¯Çüº°, Á¶Á¦ ¹× Åõ¿© °æ·Îº°, À¯Åë °æ·Îº°, Áö¿ªº°(2023-2032³â)

Infantile Spasm Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Therapeutic Class (Anticonvulsants, Corticosteroids, Others); By Drug Type; By Dosage, By Route of Administration; By Distribution Channel; and Region 2023 - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Polaris Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 117 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â 2032³â±îÁö 1¾ï 8,185¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Á¶»ç º¸°í¼­´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÅëÂû·Â°ú ¹Ì·¡ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

½ÃÀåÀº Á¦³×¸¯ ÀǾàÇ°À» Æ÷ÇÔÇÑ È¹±âÀûÀÎ ÀǾàÇ° °³¹ßÀ» ¸ñ°ÝÇÏ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, MSN Labs´Â Àεµ ÃÖÃÊÀÇ ºñ°¡¹ÙÆ®¸° Á¦³×¸¯ ÀǾàÇ°(ºñ°¡³Ø½ºÆ®)À» Ãâ½ÃÇßÀ¸¸ç, ÀÌ´Â ºÐ¸» ÇüÅ·ΠÅõ¿©µË´Ï´Ù. ÃÖ±Ù ±â¼ú ¹ßÀüÀº ƯÈ÷ ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ÀÇ »çÀü Ä¡·áÁ¦¿Í ¿¹¹æ Ä¡·áÁ¦¿¡¼­ µÎµå·¯Áö°Ô ³ªÅ¸³ª°í ÀÖÀ¸¸ç, ¿¹¸¦ µé¾î ºñħ½ÀÀû ÀÚµ¿ ¹ßÀÛ °¨Áö ÀåÄ¡ÀÇ °³¹ß·Î ¹ßÀÛÀ» Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖ´Â ºñħ½ÀÀû ÀÚµ¿ ¹ßÀÛ °¨Áö ÀåÄ¡°¡ °³¹ßµÇ¾î ÀÌ Àå¾Ö¸¦ Ä¡·áÇÒ ¼ö ÀÖ´Â ´õ ³ªÀº ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ¿ø°Ý »ó´ãÀÇ Á¸Àç·Î ÀÎÇØ ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀåÀº °¨±Ý ½Ã´ë¿¡ ³Î¸® »ç¿ëµÇ¾ú±â ¶§¹®¿¡ ±ÞÁõÇß½À´Ï´Ù. ÀÌ ¾öû³­ ¼ö¿ä´Â ½±°í Æí¾ÈÇÑ °ËÁø, ¼¼°è »ó´ã µîÀÇ ÀåÁ¡À¸·Î ÀÎÇØ Å« ¼ö¿ä¸¦ º¸¿´½À´Ï´Ù.

¼¼°èÀûÀ¸·Î ¸Å³â 12¿ù ù° ÁÖ¿¡ ¿­¸®´Â '¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ÀÎ½Ä ÁÖ°£'°ú °°Àº ÀÎ½Ä °³¼± Ä·ÆäÀÎÀÌ Á¸ÀçÇÏ°í Áõ°¡ÇÏ°í ÀÖ´Â °ÍÀº ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡´Â µ¥ ±â¿©ÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ°¡ ÁýÁßµÇ¾î ½Å¾à °³¹ßÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½Å±Ô ¹× ÀûÇÕ¼º ³ôÀº ÀǾàÇ°¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù. ¼¼°èÀºÇà ÀÚ·á¿¡ µû¸£¸é ¼¼°è GDPÀÇ 2.63%°¡ ½ÃÁß¿¡¼­ ±¸ÇÒ ¼ö ÀÖ´Â Ä¡·áÁ¦¸¦ ´ëüÇÒ ¼ö ÀÖ´Â ´õ ³ªÀº Ä¡·áÁ¦ÀÇ ¿¬±¸°³¹ß¿¡ ÅõÀڵǰí ÀÖ½À´Ï´Ù.

¼Ò¾Æ °æ·ÃÄ¡·áÁ¦ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

Ç×°æ·ÃÁ¦°¡ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÕ´Ï´Ù. ÀÌ´Â ³ôÀº È¿°ú¿Í Ä¡·á Áß È¯ÀÚÀÇ ³»¾à¼ºÀÌ ¿ëÀÌÇϱ⠶§¹®ÀÔ´Ï´Ù.

ºÎ½ÅÇÇÁúÀÚ±ØÈ£¸£¸ó ºÎ¹®Àº ¾ÈÀü¼º°ú È¿°ú·Î ÀÎÇØ ÀÓ»óÀÇ¿Í Ã³¹æÀÚ°¡ ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦·Î ¼±È£ÇÏ°í ÀÖ¾î °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÏ°í ÀÖ½À´Ï´Ù.

¼Ò¾Æ ȯÀÚ¿¡°Ô Åõ¿©Çϱ⠽±°í, ȯÀÚÀÇ ¼øÀÀµµ°¡ ³ôÀ¸¸ç, ºü¸¥ È¿°ú ¹ßÇö µîÀÇ ÀåÁ¡À¸·Î ÀÎÇØ ¾×»ó ºÎ¹®ÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÏ°í ÀÖ½À´Ï´Ù.

¼Ò¾Æ °æ·Ã Ä¡·áÁ¦´Â ÀÇ»çÀÇ ÀÔȸÇÏ¿¡ º¹¿ëÇØ¾ß ÇÏ°í, º´¿ø ¾à±¹Àº ´Ù¸¥ À¯Åë ÇüÅ¿¡ ºñÇØ ÆíÀǼºÀÌ ³ô±â ¶§¹®¿¡ º´¿ø ºÎ¹®ÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÏ°í ÀÖ½À´Ï´Ù.

ºÏ¹Ì°¡ ½ÃÀåÀ» µ¶Á¡ÇÏ°í ÀÖ´Â ÀÌÀ¯´Â ±â¼úÀÌ ÀÏÂïºÎÅÍ ¹Þ¾Æµé¿©Áö°í, ÀÇ·á ÀÎÇÁ¶ó°¡ ´õ Àß °®Ãß¾îÁ® ÀÖÀ¸¸ç, Á¦Ç° Çõ½ÅÀÌ Áö¼ÓÀûÀ¸·Î ÃßÁøµÇ°í Àֱ⠶§¹®ÀÔ´Ï´Ù.

½ÃÀåÀÇ ÁÖ¿ä ¾÷ü·Î´Â Lundbeck, Mallinckrodt Pharmaceuticals, Market Catalyst Pharmaceuticals, GW Pharmaceuticals, Retrophin, Valerion Therapeutics, Orphelia Pharma, Insys Therapeutics, Anavex Life Sciences µîÀÌ ÀÖ´Ù, Orphelia Pharma, Insys Therapeutics, Anavex Life Sciences µîÀÌ ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¼¼°èÀÇ ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå¿¡ °üÇÑ ÀλçÀÌÆ®

  • ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ - ¾÷°è ÇöȲ
  • ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀΰú ±âȸ
    • ¼ºÀå ¾ïÁ¦¿äÀΰú °úÁ¦
  • PESTLE ºÐ¼®
  • ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ¾÷°è µ¿Çâ
  • COVID-19ÀÇ ¿µÇ⠺м®

Á¦5Àå ¼¼°èÀÇ ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, Ä¡·áÁ¦ Ŭ·¡½ºº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
  • Ç×°æ·ÃÁ¦
  • ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å
  • ±âŸ

Á¦6Àå ¼¼°èÀÇ ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, Ä¡·áÁ¦ À¯Çüº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
  • ºñ°¡¹ÙÆ®¸°
  • ºÎ½ÅÇÇÁú ÀÚ±Ø È£¸£¸ó
  • ±âŸ(´Ü°è¥²)

Á¦7Àå ¼¼°èÀÇ ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, Á¶Á¦º°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
  • °íü
  • ¾×ü

Á¦8Àå ¼¼°èÀÇ ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, Åõ¿© °æ·Îº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
  • °æ±¸
  • ºñ°æ±¸
  • ±âŸ

Á¦9Àå ¼¼°èÀÇ ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, À¯Åë ä³Îº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦10Àå ¼¼°èÀÇ ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, Áö¿ªº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
    • ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå Æò°¡, Áö¿ªº°, 2019-2032³â
  • ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå - ºÏ¹Ì
    • ºÏ¹Ì : ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, Ä¡·áÁ¦ Ŭ·¡½ºº°, 2019-2032³â
    • ºÏ¹Ì : ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, Åõ¿© °æ·Îº°, 2019-2032³â
    • ºÏ¹Ì : ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, Ä¡·áÁ¦ À¯Çüº°, 2019-2032³â
    • ºÏ¹Ì : ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, Á¶Á¦º°, 2019-2032³â
    • ºÏ¹Ì : ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, À¯Åë ä³Îº°, 2019-2032³â
    • ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå - ¹Ì±¹
    • ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå - ij³ª´Ù
  • ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå - À¯·´
    • À¯·´ : ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, Ä¡·áÁ¦ Ŭ·¡½ºº°, 2019-2032³â
    • À¯·´ : ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, Åõ¿© °æ·Îº°, 2019-2032³â
    • À¯·´ : ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, Ä¡·áÁ¦ À¯Çüº°, 2019-2032³â
    • À¯·´ : ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, Á¶Á¦º°, 2019-2032³â
    • À¯·´ : ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, À¯Åë ä³Îº°, 2019-2032³â
    • ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå - ¿µ±¹
    • ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå - ÇÁ¶û½º
    • ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå - µ¶ÀÏ
    • ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå - ÀÌÅ»¸®¾Æ
    • ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå - ½ºÆäÀÎ
    • ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå - ³×´ú¶õµå
    • ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå - ·¯½Ã¾Æ
  • ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå - ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, Ä¡·áÁ¦ Ŭ·¡½ºº°, 2019-2032³â
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, Åõ¿© °æ·Îº°, 2019-2032³â
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, Ä¡·áÁ¦ À¯Çüº°, 2019-2032³â
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, Á¶Á¦º°, 2019-2032³â
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, À¯Åë ä³Îº°, 2019-2032³â
    • ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå - Áß±¹
    • ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå - Àεµ
    • ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå - ÀϺ»
    • ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå - ¸»·¹À̽þÆ
    • ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå - Àεµ³×½Ã¾Æ
    • ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå - Çѱ¹
  • ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå - Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, Ä¡·áÁ¦ Ŭ·¡½ºº°, 2019-2032³â
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, Åõ¿© °æ·Îº°, 2019-2032³â
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, Ä¡·áÁ¦ À¯Çüº°, 2019-2032³â
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, Á¶Á¦º°, 2019-2032³â
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, À¯Åë ä³Îº°, 2019-2032³â
    • ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå - »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå - ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå - À̽º¶ó¿¤
    • ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå - ³²¾ÆÇÁ¸®Ä«
  • ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå - ¶óƾ¾Æ¸Þ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä« : ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, Ä¡·áÁ¦ Ŭ·¡½ºº°, 2019-2032³â
    • ¶óƾ¾Æ¸Þ¸®Ä« : ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, Åõ¿© °æ·Îº°, 2019-2032³â
    • ¶óƾ¾Æ¸Þ¸®Ä« : ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, Ä¡·áÁ¦ À¯Çüº°, 2019-2032³â
    • ¶óƾ¾Æ¸Þ¸®Ä« : ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, Á¶Á¦º°, 2019-2032³â
    • ¶óƾ¾Æ¸Þ¸®Ä« : ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå, À¯Åë ä³Îº°, 2019-2032³â
    • ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå - ¸ß½ÃÄÚ
    • ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå - ºê¶óÁú
    • ¼Ò¾Æ °æ·Ã Ä¡·áÁ¦ ½ÃÀå - ¾Æ¸£ÇîƼ³ª

Á¦11Àå °æÀï ±¸µµ

  • È®Àå ¹× Àμö ºÐ¼®
    • È®Àå
    • Àμö
  • Á¦ÈÞ/Çù¾÷/ÇÕÀÇ/°ø°³

Á¦12Àå ±â¾÷ °³¿ä

  • Lundbeck
  • Mallinckrodt Pharmaceuticals
  • Catalyst Pharmaceuticals
  • GW Pharmaceuticals
  • Retrophin
  • Valerion Therapeutics
  • Orphelia Pharma
  • Insys Therapeutics
  • Anavex Life Sciences Corp
LSH 23.09.15

The infantile spasm therapeutics market size is expected to reach USD 181.85 million by 2032, according to a new study by Polaris Market Research. The report "Infantile Spasm Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Therapeutic Class (Anticonvulsants, Corticosteroids, Others); By Drug Type; By Dosage, By Route of Administration; By Distribution Channel; and Region 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Market has witnessed some revolutionary drug developments including generic drugs, for e.g., MSN Labs launched India's first generic Vigabatrin (Viganext) that is to be administered as a powder. The recent technological advancements particularly in advance treatment and preventive treatment of Infantile Spasm Therapeutics, like development of non-invasive automated seizure detection device that help in early detection of seizure to provide better solutions for to treat the disorder. Due to presence of telemedicine and teleconsultation, during the times of COVID-19, Infantile Spasm Therapeutics market has seen a jump as it was widely used during the times of lockdown. This huge demand was seen due to the advantages of easy and comfortable check-up, consultation from across the globe amongst others.

The presence and increase of awareness campaigns like that of Infantile Spasm Therapeutics Awareness Week every first week of December across the globe contribute to positively impacting the market. Also, the growing demand for novel and compliant drugs is made possible by an increasing concentration on investments associated to research and development, which leads to an increase in new drug development. According to World Bank data, 2.63% of global GDP is invested in research and development of better alternatives to the drugs available in the market.

Infantile Spasm Therapeutics Market Report Highlights

The anticonvulsants segment accounted for the largest revenue share. This is due to its higher efficacy and ease of tolerance in patients undergoing treatment

Adrenocorticotropic hormone segment accounted to hold largest revenue share as it is preferred by the clinicians and prescribers to treat Infantile Spasm Therapeutics owing to its safety and efficacy making it the drug of choice

Liquid segment accounted for largest market share due to its advantages like ease of administration in infantile patients, high patient compliance, and rapid onset of action

Hospital Pharmacy segment account for a largest market share owing to the reason that Infantile Spasm Therapeutics requires treatment in presence of a medical practitioner and, hospital pharmacies provide convenience as compared to other modes of distribution

North America dominated the market as there is more early acceptance of techniques, better and more developed healthcare infrastructure and constant drive for product innovation.

The major players in the market include Lundbeck, Mallinckrodt Pharmaceuticals, Catalyst Pharmaceuticals, GW Pharmaceuticals, Retrophin, Valerion Therapeutics, Orphelia Pharma, Insys Therapeutics, & Anavex Life Sciences.

Polaris Market Research has segmented the Infantile Spasm Therapeutics market report based on therapeutic class, dosage, route of administration, distribution channel, drug type, and region:

Infantile Spasm Therapeutics Market, Therapeutic Class Outlook (Revenue - USD Million, 2019 - 2032)

  • Anticonvulsants
  • Corticosteroids
  • Others

Infantile Spasm Therapeutics Market, Drug Type Outlook (Revenue - USD Million, 2019 - 2032)

  • Vigabatrin
  • Adrenocorticotropic Hormone
  • Others (Phase III)

Infantile Spasm Therapeutics Market, Dosage Outlook (Revenue - USD Million, 2019 - 2032)

  • Solid
  • Liquid

Infantile Spasm Therapeutics Market, Route of Administration Outlook (Revenue - USD Million, 2019 - 2032)

  • Oral
  • Parenteral
  • Others

Infantile Spasm Therapeutics Market, Distribution Channel Outlook (Revenue - USD Million, 2019 -2032)

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Infantile Spasm Therapeutics Market, Region Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Infantile Spasm Therapeutics Market Insights

  • 4.1. Infantile Spasm Therapeutics - Industry Snapshot
  • 4.2. Infantile Spasm Therapeutics Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising incidence of infantile spasms in newborns
      • 4.2.1.2. Increasing government supports
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost of treatment
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Infantile Spasm Therapeutics Industry Trends
  • 4.6. COVID-19 Impact Analysis

5. Global Infantile Spasm Therapeutics Market, by Therapeutic Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
  • 5.3. Anticonvulsants
    • 5.3.1. Global Infantile Spasm Therapeutics Market, by Anticonvulsants, by Region, 2019-2032 (USD Million)
  • 5.4. Corticosteroids
    • 5.4.1. Global Infantile Spasm Therapeutics Market, by Corticosteroids, by Region, 2019-2032 (USD Million)
  • 5.5. Others
    • 5.5.1. Global Infantile Spasm Therapeutics Market, by Others, by Region, 2019-2032 (USD Million)

6. Global Infantile Spasm Therapeutics Market, by Drug Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
  • 6.3. Vigabatrin
    • 6.3.1. Global Infantile Spasm Therapeutics Market, by Vigabatrin, by Region, 2019-2032 (USD Million)
  • 6.4. Adrenocorticotropic Hormone
    • 6.4.1. Global Infantile Spasm Therapeutics Market, by Adrenocorticotropic Hormone, by Region, 2019-2032 (USD Million)
  • 6.5. Others (Phase III)
    • 6.5.1. Global Infantile Spasm Therapeutics Market, by Others (Phase III), by Region, 2019-2032 (USD Million)

7. Global Infantile Spasm Therapeutics Market, by Dosage

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
  • 7.3. Solid
    • 7.3.1. Global Infantile Spasm Therapeutics Market, by Solid, by Region, 2019-2032 (USD Million)
  • 7.4. Liquid
    • 7.4.1. Global Infantile Spasm Therapeutics Market, by Liquid, by Region, 2019-2032 (USD Million)

8. Global Infantile Spasm Therapeutics Market, by Route of Administration

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
  • 8.3. Oral
    • 8.3.1. Global Infantile Spasm Therapeutics Market, by Oral, by Region, 2019-2032 (USD Million)
  • 8.4. Parenteral
    • 8.4.1. Global Infantile Spasm Therapeutics Market, by Parenteral, by Region, 2019-2032 (USD Million)
  • 8.5. Others
    • 8.5.1. Global Infantile Spasm Therapeutics Market, by Others, by Region, 2019-2032 (USD Million)

9. Global Infantile Spasm Therapeutics Market, by Distribution Channel

  • 9.1. Key Findings
  • 9.2. Introduction
    • 9.2.1. Global Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
  • 9.3. Hospital Pharmacy
    • 9.3.1. Global Infantile Spasm Therapeutics Market, by Hospital Pharmacy, by Region, 2019-2032 (USD Million)
  • 9.4. Retail Pharmacy
    • 9.4.1. Global Infantile Spasm Therapeutics Market, by Retail Pharmacy, by Region, 2019-2032 (USD Million)
  • 9.5. Online Pharmacy
    • 9.5.1. Global Infantile Spasm Therapeutics Market, by Online Pharmacy, by Region, 2019-2032 (USD Million)

10. Global Infantile Spasm Therapeutics Market, by Geography

  • 10.1. Key findings
  • 10.2. Introduction
    • 10.2.1. Infantile Spasm Therapeutics Market Assessment, By Geography, 2019-2032 (USD Million)
  • 10.3. Infantile Spasm Therapeutics Market - North America
    • 10.3.1. North America: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
    • 10.3.2. North America: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
    • 10.3.3. North America: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
    • 10.3.4. North America: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
    • 10.3.5. North America: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.3.6. Infantile Spasm Therapeutics Market - U.S.
      • 10.3.6.1. U.S.: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.3.6.2. U.S.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.3.6.3. U.S.: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.3.6.4. U.S.: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.3.6.5. U.S.: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.3.7. Infantile Spasm Therapeutics Market - Canada
      • 10.3.7.1. Canada: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.3.7.2. Canada.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.3.7.3. Canada: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.3.7.4. Canada: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.3.7.5. Canada: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
  • 10.4. Infantile Spasm Therapeutics Market - Europe
    • 10.4.1. Europe: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
    • 10.4.2. Europe.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
    • 10.4.3. Europe: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
    • 10.4.4. Europe: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
    • 10.4.5. Europe: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.4.6. Infantile Spasm Therapeutics Market - UK
      • 10.4.6.1. UK: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.4.6.2. UK.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.4.6.3. UK: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.4.6.4. UK: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.4.6.5. UK: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.4.7. Infantile Spasm Therapeutics Market - France
      • 10.4.7.1. France: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.4.7.2. France.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.4.7.3. France: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.4.7.4. France: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.4.7.5. France: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.4.8. Infantile Spasm Therapeutics Market - Germany
      • 10.4.8.1. Germany: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.4.8.2. Germany.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.4.8.3. Germany: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.4.8.4. Germany: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.4.8.5. Germany: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.4.9. Infantile Spasm Therapeutics Market - Italy
      • 10.4.9.1. Italy: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.4.9.2. Italy.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.4.9.3. Italy: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.4.9.4. Italy: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.4.9.5. Italy: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.4.10. Infantile Spasm Therapeutics Market - Spain
      • 10.4.10.1. Spain: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.4.10.2. Spain.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.4.10.3. Spain: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.4.10.4. Spain: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.4.10.5. Spain: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.4.11. Infantile Spasm Therapeutics Market - Netherlands
      • 10.4.11.1. Netherlands: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.4.11.2. Netherlands.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.4.11.3. Netherlands: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.4.11.4. Netherlands: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.4.11.5. Netherlands: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.4.12. Infantile Spasm Therapeutics Market - Russia
      • 10.4.12.1. Russia: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.4.12.2. Russia.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.4.12.3. Russia: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.4.12.4. Russia: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.4.12.5. Russia: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
  • 10.5. Infantile Spasm Therapeutics Market - Asia Pacific
    • 10.5.1. Asia Pacific: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
    • 10.5.2. Asia Pacific.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
    • 10.5.3. Asia Pacific: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
    • 10.5.4. Asia Pacific: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
    • 10.5.5. Asia Pacific: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.5.6. Infantile Spasm Therapeutics Market - China
      • 10.5.6.1. China: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.5.6.2. China.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.5.6.3. China: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.5.6.4. China: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.5.6.5. China: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.5.7. Infantile Spasm Therapeutics Market - India
      • 10.5.7.1. India: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.5.7.2. India.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.5.7.3. India: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.5.7.4. India: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.5.7.5. India: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.5.8. Infantile Spasm Therapeutics Market - Japan
      • 10.5.8.1. Japan: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.5.8.2. Japan.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.5.8.3. Japan: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.5.8.4. Japan: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.5.8.5. Japan: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.5.9. Infantile Spasm Therapeutics Market - Malaysia
      • 10.5.9.1. Malaysia: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.5.9.2. Malaysia.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.5.9.3. Malaysia: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.5.9.4. Malaysia: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.5.9.5. Malaysia: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.5.10. Infantile Spasm Therapeutics Market - Indonesia
      • 10.5.10.1. Indonesia: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.5.10.2. Indonesia.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.5.10.3. Indonesia: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.5.10.4. Indonesia: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.5.10.5. Indonesia: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.5.11. Infantile Spasm Therapeutics Market - South Korea
      • 10.5.11.1. South Korea: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.5.11.2. South Korea.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.5.11.3. South Korea: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.5.11.4. South Korea: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.5.11.5. South Korea: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
  • 10.6. Infantile Spasm Therapeutics Market - Middle East & Africa
    • 10.6.1. Middle East & Africa: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
    • 10.6.2. Middle East & Africa: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
    • 10.6.3. Middle East & Africa: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
    • 10.6.4. Middle East & Africa: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
    • 10.6.5. Middle East & Africa: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.6.6. Infantile Spasm Therapeutics Market - Saudi Arabia
      • 10.6.6.1. Saudi Arabia: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.6.6.2. Saudi Arabia.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.6.6.3. Saudi Arabia: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.6.6.4. Saudi Arabia: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.6.6.5. Saudi Arabia: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.6.7. Infantile Spasm Therapeutics Market - UAE
      • 10.6.7.1. UAE: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.6.7.2. UAE.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.6.7.3. UAE: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.6.7.4. UAE: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.6.7.5. UAE: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.6.8. Infantile Spasm Therapeutics Market - Israel
      • 10.6.8.1. Israel: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.6.8.2. Israel.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.6.8.3. Israel: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.6.8.4. Israel: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.6.8.5. Israel: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.6.9. Infantile Spasm Therapeutics Market - South Africa
      • 10.6.9.1. South Africa: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.6.9.2. South Africa.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.6.9.3. South Africa: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.6.9.4. South Africa: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.6.9.5. South Africa: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
  • 10.7. Infantile Spasm Therapeutics Market - Latin America
    • 10.7.1. Latin America: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
    • 10.7.2. Latin America.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
    • 10.7.3. Latin America: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
    • 10.7.4. Latin America: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
    • 10.7.5. Latin America: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.7.6. Infantile Spasm Therapeutics Market - Mexico
      • 10.7.6.1. Mexico: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.7.6.2. Mexico.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.7.6.3. Mexico: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.7.6.4. Mexico: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.7.6.5. Mexico: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.7.7. Infantile Spasm Therapeutics Market - Brazil
      • 10.7.7.1. Brazil: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.7.7.2. Brazil.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.7.7.3. Brazil: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.7.7.4. Brazil: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.7.7.5. Brazil: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)
    • 10.7.8. Infantile Spasm Therapeutics Market - Argentina
      • 10.7.8.1. Argentina: Infantile Spasm Therapeutics Market, by Therapeutic Class, 2019-2032 (USD Million)
      • 10.7.8.2. Argentina.: Infantile Spasm Therapeutics Market, by Route of Administration, 2019-2032 (USD Million)
      • 10.7.8.3. Argentina: Infantile Spasm Therapeutics Market, by Drug Type, 2019-2032 (USD Million)
      • 10.7.8.4. Argentina: Infantile Spasm Therapeutics Market, by Dosage, 2019-2032 (USD Million)
      • 10.7.8.5. Argentina: Infantile Spasm Therapeutics Market, by Distribution Channel, 2019-2032 (USD Million)

11. Competitive Landscape

  • 11.1. Expansion and Acquisition Analysis
    • 11.1.1. Expansion
    • 11.1.2. Acquisitions
  • 11.2. Partnerships/Collaborations/Agreements/Exhibitions

12. Company Profiles

  • 12.1. Lundbeck
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Benchmarking
    • 12.1.4. Recent Development
  • 12.2. Mallinckrodt Pharmaceuticals
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Benchmarking
    • 12.2.4. Recent Development
  • 12.3. Catalyst Pharmaceuticals
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Benchmarking
    • 12.3.4. Recent Development
  • 12.4. GW Pharmaceuticals
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Benchmarking
    • 12.4.4. Recent Development
  • 12.5. Retrophin
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Benchmarking
    • 12.5.4. Recent Development
  • 12.6. Valerion Therapeutics
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Benchmarking
    • 12.6.4. Recent Development
  • 12.7. Orphelia Pharma
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Benchmarking
    • 12.7.4. Recent Development
  • 12.8. Insys Therapeutics
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Benchmarking
    • 12.8.4. Recent Development
  • 12.9. Anavex Life Sciences Corp
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Benchmarking
    • 12.9.4. Recent Development
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦